Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Recipient : Fusion Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Fusion has global rights to discover, develop and commercialize any peptide-based radiopharmaceuticals, including lead program, FPI-1434 for the treatment of various solid tumors under the collaboration.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 01, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Recipient : Fusion Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : PneoVCA,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PneoVCA is designed to target certain proteins (neoantigens) on individuals’ tumor cells. Combination immunotherapy with mAB, such as pembrolizumab, may help the body’s immune system attack the cancer and thereby interfere with ability of tumor cells...
Product Name : PneoVCA
Product Type : Vaccine
Upfront Cash : Inapplicable
June 28, 2022
Lead Product(s) : PneoVCA,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Mayo Clinic
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
